Lara Longpre - 31 Jan 2023 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role: Chief Development Officer
Signature: /s/ Jody Howe, Attorney-in-Fact
Issuer symbol: MIRM
Transactions as of: 31 Jan 2023
Net transactions value: $0
Form type: 4
Filing time: 02 Feb 2023, 16:46:23 UTC
Previous filing: 14 Nov 2022
Next filing: 19 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MIRM	Common Stock	Award	$0	+9,625	+10%	$0.000000	106,159	31 Jan 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MIRM	Stock Option (right to buy)	Award	$0	+38,500		$0.000000	38,500	31 Jan 2023	Common Stock	38,500	$23.48	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan.
F2	1/4th of the shares vest one year after January 31, 2023 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.